Trombosis y anticoagulación en la mujer

Vasan, 1997, Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation, Circulation., 96, 1863, 10.1161/01.CIR.96.6.1863 Rosenkranz-Weiss, 1994, Gender-specific differences in expression of mRNAs for functional and structural proteins in rat ventricular myocardium, J Mol Cell Cardiol., 26, 261, 10.1006/jmcc.1994.1029 Huxley, 2007, Sex and the cardiovascular system: the intriguing tale of how women and men regulate cardiovascular function differently, Adv Physiol Educ., 31, 17, 10.1152/advan.00099.2006 Celentano, 2003, Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults, J Hypertens., 21, 1415, 10.1097/00004872-200307000-00033 Becker, 2006, Sex differences in platelet reactivity and response to low-dose aspirin therapy, JAMA., 295, 1420, 10.1001/jama.295.12.1420 Kurrelmeyer, 2003, Platelet hyperreactivity in women from families with premature atherosclerosis, J Am Med Womens Assoc., 58, 272 Faraday, 1997, Gender differences in platelet GPIIb–IIIa activation, Thromb. Haemost., 77, 748, 10.1055/s-0038-1656045 Woodward, 2003, C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease, Br J Haematol., 122, 135, 10.1046/j.1365-2141.2003.04387.x Woodward, 1997, Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease, Br. J. Haematol., 97, 785, 10.1046/j.1365-2141.1997.1232935.x Lowe, 1997, Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey I. Illustrative reference ranges by age, sex and hormone use, Br J Haematol., 97, 775, 10.1046/j.1365-2141.1997.1222936.x Rothwell, 2005, population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study), Lancet., 366, 1773, 10.1016/S0140-6736(05)67702-1 Kyrle, 2004, The risk of recurrent venous thromboembolism in men and women, N Engl J Med., 350, 2558, 10.1056/NEJMoa032959 McRae, 2006, Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis, Lancet, 368, 371, 10.1016/S0140-6736(06)69110-1 Arnlov, 2006, Endogenous sex hormones and cardiovascular disease incidence in men, Ann Intern Med., 145, 176, 10.7326/0003-4819-145-3-200608010-00005 Bushnell, 2008, Stroke and the female brain, Nat Clin Pract Neurol., 4, 22, 10.1038/ncpneuro0686 Daly, 1996, Risk of venous thromboembolism in users of hormone replacement therapy, Lancet., 348, 977, 10.1016/S0140-6736(96)07113-9 Jick, 1996, Risk of acute myocardial infarction and low-dose combined oral contraceptives, Lancet., 347, 627, 10.1016/S0140-6736(96)91334-3 Grodstein, 1996, Prospective study of exogenous hormones and risk of pulmonary embolism in women, Lancet., 348, 983, 10.1016/S0140-6736(96)07308-4 Handenbroucke, 2001, Oral contraceptives and the risk of venous thrombosis, N Engl J Med., 344, 1527, 10.1056/NEJM200105173442007 Nordstrom Sm, 2008, Sex differences in thrombosis, Expert Rev. Hematol., 1, 3, 10.1586/17474086.1.1.3 Vehkavaara, 2001, Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women, Thromb. Haemost., 85, 619, 10.1055/s-0037-1615643 Scarabin, 2003, Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, Lancet., 362, 428, 10.1016/S0140-6736(03)14066-4 Patti, 2014, Platelet function long-term antiplatelet therapy in women: is there a gender-specificity?A. ‘state-of-the-art’ paper, Eur Heart J., 35, 2213, 10.1093/eurheartj/ehu279 Alexander, 2006, Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative, Circulation., 114, 1380, 10.1161/CIRCULATIONAHA.106.620815 Ahmed, 2009, Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the Northern New England Percutaneous Coronary Intervention Registry, Circ Cardiovasc Interv., 2, 423, 10.1161/CIRCINTERVENTIONS.109.860494 Gutiérrez-Chico, 2013, Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention, Drugs., 73, 1921, 10.1007/s40265-013-0135-y Cohen, 2001, Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups, J Thromb Thrombolysis., 12, 199, 10.1023/A:1015259706522 White, 2006, Am Heart J., 152, 1042, 10.1016/j.ahj.2006.08.002 Antman, 2006, Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction, N Engl J Med., 354, 1477, 10.1056/NEJMoa060898 Chacko, 2006, Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, Am Heart J., 151, 10.1016/j.ahj.2006.02.012 Lansky, 2009, Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial), Am J Cardiol., 103, 1196, 10.1016/j.amjcard.2009.01.030 Madsen, 2008, Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatment, EuroIntervention., 3, 610, 10.4244/EIJV3I5A109 Stone, 2008, Bivalirudin during primary PCI in acute myocardial infarction, N Engl J Med., 358, 2218, 10.1056/NEJMoa0708191 Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-76. Yusuf, 2006, Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial, JAMA., 295, 1519, 10.1001/jama.295.13.joc60038 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med., 363, 2499, 10.1056/NEJMoa1007903 Büller, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Patel, 2011, Rivaroxaban versus warfarin in non valvular atrial fibrillation, N Engl J Med., 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med., 365, 981, 10.1056/NEJMoa1107039 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, 1406, 10.1056/NEJMoa1306638 Avgil Tsadok, 2012, Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation, JAMA., 307, 1952, 10.1001/jama.2012.3490 Fang, 2005, Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study, Circulation., 112, 1687, 10.1161/CIRCULATIONAHA.105.553438 Gomberg-Maitland, 2006, Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials, Eur Heart J., 27, 1947, 10.1093/eurheartj/ehl103 Cheng, 2016, gender differences of thromboembolic events in atrial fibrillation, Am J Cardiol., 117, 1021e, 10.1016/j.amjcard.2015.12.040 Fang, 2005, Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors in Atrial fibrillation (ATRIA) study, Circulation., 112, 1687e, 10.1161/CIRCULATIONAHA.105.553438 Wagstaff, 2014, Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation?. A systematic review and meta-analysis, QJM., 107, 955e967, 10.1093/qjmed/hcu054 Friberg, 2012, Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study, Br Med J, 344e Dagres, 2007, Gender related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe, J Am Coll Cardiol., 49, 572e, 10.1016/j.jacc.2006.10.047 Sabouret, 2014, Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation in General Practice) database, Clin Res Cardiol., 103, 887e, 10.1007/s00392-014-0726-y Sullivan, 2012, Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM), Am J Cardiol., 110, 1799e, 10.1016/j.amjcard.2012.08.014